Main Industry
Biotechnology
Main Product/Service
REGiMMUNE’s lead product candidate is RGI-2001, a liposomal small-molecule agent designed to expand regulatory T cells for the prevention of acute graft-versus-host disease (aGvHD). The company also is developing antibody and cell-therapy candidates to ei
The content above was translated by Ai
Founded Year
2018
Unified Business No.
50779876
Status
Active
Number of Employees
0
Total Paid-in
Capital
240,962,510 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
REGiMMUNE is a clinical-stage biopharmaceutical company focused on creating innovative immunotherapies by harnessing the power of regulatory T cells (Tregs). Their mission is: “Delivering breakthrough immune medicines by harnessing the power of regulatory T cells.”
The content above was translated by Ai
